Thievon-Wright Consulting Group is a wholly owned subsidiary of Evolution Research Group, LLC and manages an elite network of experienced, owned and affiliated, clinical research sites geographically dispersed across the U.S. and Puerto Rico. Evolution Research Group is the largest, independent clinical research site company in the US and the leader in CNS clinical study execution. Our group of inpatient and outpatient, early and late phase research units, is focused on conducting simple and highly complex trials in psychiatric and neurologic disorder, pain indications, addictions, sleep disorders as well as several non-CNS indications.

MEET US AT THESE UPCOMING CONFERENCES

American Pain Society (APS)
May 17 - May 20
Pittsburgh, PA

American Society of Clinical Psychopharmacology
(ASCP formerly NCDEU)
May 29 - June 2
Miami Beach, FL

SLEEP 2017
June 3 - 7
Boston, MA

Alzheimer’s Association International Conference (AAIC)
July 16 – 20
London, England

In an attempt to expand our public awareness, Evolution Research Group, Thievon-Wright Consulting Group and all Portfolio Sites are now on Facebook and Twitter. To learn more about our clinical research sites and their community outreach efforts follow us at:

@TWCGResearch
@ERGResearch

Endeavor Joins the Network

Endeavor Clinical Trials of San Antonio, Texas is the newest addition to the ERG affiliate network. Endeavor specializes in post-op pain studies such as bunionectomy, breast augmentation and abdominoplasty, as well as diabetic neuropathy, T2DM, diabetic foot ulcers, etc.

Dr. Richard Pollak (founder) is a KOL in podiatric research and looks forward to collaborating with our pain specialists across the company.

CPMI Partners with Sponsors and CROs for Large Inpatient Phase I and Special Population Studies

CPMI joined Evolution Research Group less than a year ago, and has been a tremendous addition to the Evolution Research Group organization. They work closely with their clinical research organization and sponsor clients to deliver high quality data, on time and within budget. With Evolution Research Group’s infrastructure relieving CPMI of the burden of financial and administrative responsibilities, the clinical operations team has been able to flourish and offer expanded services to the industry. CPMI has a 30-year history of providing its clients with unique capabilities, executing on complex trials in normal healthy volunteers and highly specialized populations. Well known for its ability to enroll in studies targeting renal insufficiency, hepatic impairment, T2DM, dermatology, elderly healthy subjects, post-menopausal women, sexual dysfunction (male and female), smoking cessation and obesity, CPMI continues to expand into new indications.

The 120-bed Phase I unit is a preferred site for many large pharmaceutical sponsors, biotechnology and specialty pharmaceutical companies. Additionally, several clinical research organization clients trust CPMI’s established team to deliver when their own Phase I units are at capacity or a multi-center approach is needed. With veterans Dr. Kenneth Lasseter, Stacy Dilzer and Cooper Shamblen leading the team, CPMI has successfully completed hundreds of FIM, PK/PD, SAD/MAD, DDI, TQT, food effect, and BA/BE studies.

Evolution Research Group’s service offering is greatly enhanced by CPMI’s clinical pharmacology expertise, enabling Evolution Research Group to meet its clients’ needs throughout the lifecycle of a compound’s development.

In-Situ Glocal Trials Network, LLC, Puerto Rico Joins Evolution Research Group

Evolution Research Group is thrilled to announce that In-Situ recently joined our affiliate site network, adding multi-therapeutic capabilities and access to a large Hispanic population in Puerto Rico. With 32 network physicians covering 12 specialty/subspecialty areas with large private practices, In-Situ offers a unique opportunity for sponsors and clinical research organizations. Meet In-Situ Founder Oscar Colon-Acosta at ASCP in Miami! Additional information will be posted to our website (www.cnssites.com) very soon.
Advanced Memory Research Institute of New Jersey, Toms River, NJ – Outpatient Facility

Advanced Memory Research Institute of New Jersey, under the direction of Principal Investigator and President Dr. Sanjiv Sharma, continues to significantly meet and exceed enrollment for trials in Alzheimer’s disease, dementia, and MCI. Dr. Sharma and his staff are currently working on over 10 protocols and in these protocols, the site has a low screen fail rate and of those screened 80 percent are randomized. AMRINJ prides itself on a high completion rate and maintaining a strong relationship with its patients. AMRINJ is also looking to expand into other areas of neurology including MS and Parkinson’s disease.

Alexian Brothers Neurosciences Institute, Elk Grove Village, IL – Outpatient Facility

Located on the campus of Alexian Brothers Medical Center, the site specializes in neurology indications such as, Alzheimer’s disease, MCI, dementia and Parkinson’s disease. As a leader in Alzheimer’s research, Dr. Concetta Forchetti is currently conducting an early symptomatic Alzheimer’s trial. The site has randomized the first subject worldwide, has more than doubled its expected enrollment and are experiencing a low screen fail rate while maintaining exceptional retention.

CBH Health, Gaithersburg, MD – 20-Bed Clinical Pharmacology Unit/Outpatient Facility

CBH Health moved into its new 20,000-square-foot facility in Gaithersburg, Md. toward the end of 2016. It consists of a secure 20-bed inpatient clinical research unit, and an outpatient unit with designated bed ward area. We have designated rooms for cognition testing. There is also an area for infusions (ketamine) that is used for both research and outpatient services. The building holds our recruitment and assessment team, administrative offices, research staff offices, monitoring space and additional exam rooms where our outpatient clients are seen for pharmacology management visits. Adjacent to these offices, there is a psychiatric rehabilitation program which sees clients that are diagnosed with schizophrenia, depression, and bipolar illness.

In 2016, CBH Health continued its early-phase biomarker collaborations with the University of Maryland/Maryland Psychiatric Research Center (UMD/MPRC). They completed a Phase Ib study in schizophrenia, enrolling 80 subjects in 10 months. In addition, CBH Health continued to be the highest enrolling site on their depression clinical trial, and began work on both acute and stable psychiatric studies for 2017.

Clinical Pharmacology of Miami, Miami, FL - 120-Bed Clinical Pharmacology Unit/Outpatient Facility

Clinilabs, New York City, NY – 50-Bed Clinical Pharmacology Unit/Outpatient Facility Eatontown, NJ – 50-Bed Clinical Pharmacology Unit/Outpatient Facility

Clinilabs offers 100 beds within its two locations for Phase I-III clinical trials. The company offers sponsors a fully-integrated suite of services, including Core Lab, that enables the sponsors to conduct their studies using a single vendor. Version 2.0 of the Clinilabs Core Data Software will be finalized by the end of 2017. Latest advances include a new epilepsy monitoring unit with video EEG, specifically for epilepsy monitoring/seizure safety studies and new EEG equipment at the New York City location. This year, Clinilabs will be conducting a human abuse liability study at its New Jersey location. Recent additions to the clinical staff include 24/7 nursing coverage, CRA (monitor) coverage throughout the U.S., and its first European employee in the Netherlands.

The Cognitive and Research Center of New Jersey, Springfield, NJ – Outpatient Facility

CRCNJ continues to provide clinical services and participation in clinical trials for patients concerned about cognitive change. In recent months, the site added an additional neuropsychologist to assist with patient assessments as well as an additional research coordinator to conduct the numerous trials. CRCNJ has been successful with its clinical trials over the past five years—we have been awarded a Gold Star status and considered as an early recruiting site. We are in the process of securing space for a second location that will service Somerset/Hunterdon counties. This location will expand our data base of clinical trial participants. Our Community Outreach Specialist continues to serve as a liaison between CRCNJ and the community, and schedules events such as free memory screens and lunch-and-learns.

Endeavor Clinical Trials, San Antonio, TX - 18-Bed Clinical Pharmacology Unit/ Outpatient Facility

Midwest Clinical Research Center, Dayton, OH – 19-Bed Clinical Pharmacology Unit/Outpatient Facility

Dr. Otto Dueno, Medical Director, has led MCRC in conducting studies in new therapeutic areas, which include treatment-resistant depression, tardive dyskinesia, opioid-use disorder, eating disorders, PTSD, essential tremors, smoking and insomnia. Along with Dr. Isabel Kuhar-Arcure, the site is focused on promoting its capabilities in Phase I, PK, bioequivalence studies, pediatric studies, insomnia and smoking. MCRC has added to its recruitment staff in order to build its patient database.

Neurology Diagnostics, Dayton, OH – Outpatient Facility

The outpatient research department at Neurology Diagnostics has been renamed as Neurology Diagnostics Research & The Memory Clinic. Due to the increased number of awarded studies to the site, the department acquired a larger dedicated research office. Also, another study coordinator joined the team to help administer ratings and manage studies. In addition to the Principal Investigator, Dr. Joel Vandersluis, there are two Certified Nurse Practitioners who serve as sub-investigators and assist in administering psychometric testing. The site is also focusing on community outreach as a way to inform the community of the importance of clinical trials and as a recruitment method.

NeuroTrials Research, Atlanta, GA – 15-Bed Clinical Research Unit/Outpatient Facility

Founded in 1997, NTR celebrates its 20th year specializing in sleep disorders and neurological disorders. The site has worked on several large sleep programs and is routinely-
identified as top enrollers on these studies. In 2016, the site was the recipient of a CRO’s Clinical Research Site award. In 2017, NTR has been selected as the only facility in Georgia, and one of 15 nationwide, to investigate the link between Parkinson’s disease and excessive sleepiness (whether this is caused by the disease or the medication). This unique POC study focuses on improving the quality of life for PD patients.

Pacific Clinical Research Medical Group, Upland, CA – Outpatient Facility

Pacific Clinical Research Medical Group is proud to announce Claudia Reyes-Navarro, RN, has joined its staff as a clinical study nurse and equally proud to announce Abhery Das has joined its staff as a clinical research coordinator. Additionally, the site continues to focus on building its elderly and adolescent database through community outreach and online and local advertisements. Recently, Dr. Paul Miller and his staff were recognized for being the top enrolling site in studies for adults with major depressive disorder and subjects over the age of 65 with major depressive disorder. The site frequently receives feedback from sponsors that are appreciative of the quality of data collection.

Pacific Research Network, San Diego, CA – 7-Bed Clinical Research Unit/PSG/Outpatient Facility Rancho Bernardo, CA - 2 Beds Clinical Research Unit/PSG/Outpatient Facility

Pacific Research Network has continued to expand over the past year. PRN’s strong presence in the community through participation in charity walks, health fairs, social media campaigns, educational symposiums and screening days has contributed to higher enrollment in its Alzheimer’s, sleep and MS trials. The site has expanded its satellite site; located just 20 miles from the main site and serving a predominantly elderly population in a well-known retirement community. The satellite is now equipped with two rooms used for inpatient and sleep trials. The certified sleep labs (both at the main site and now, satellite) continue to operate seven days per week. Collectively, these efforts have resulted in an increase in the volume of clinical trials contracted and the amount of subjects ultimately randomized.

SPRI Clinical Trials, Brooklyn, NY – Outpatient Facility

SPRI has more than 40 years of clinical trial experience in schizophrenia, depression, bipolar and Alzheimer’s, among others. In the past year, SPRI has broadened its core of therapeutic areas in psychiatry and neurology to include studies in PTSD and insomnia. SPRI continues an increased focus on pain indications, including migraine, osteoarthritis and diabetic painful neuropathy. The site fosters relationships in the community with local multispecialty clinics and conducting regular free memory screenings.

St. Louis Clinical Trials, St. Louis, MO – 55-Bed Clinical Pharmacology Unit/Outpatient Facility

The site welcomes Sean Faggioli, Early Phase Services Project Lead. Sean comes to us with six years of early phase experience, with five years of experience managing the set up and conduct of human abuse liability trials. Sean will partner with Dr. Daniel Gruener, Medical Director, to expand our capabilities in pain management, addiction and HAL.

Woodland International Research Group, Little Rock, AR – 40-Bed Clinical Research Unit / 16 Bed Pediatric Clinical Research Unit

In July 2016, WIRG opened its new Pediatric Unit. This purpose-built, 16-bed CRU was designed for child and adolescent inpatient trials in special populations with CNS disorders and diseases in other therapeutic areas. Phase I studies performed at WIRG include schizophrenia, bipolar disorders, ADHD, depression and GERD.

The unit features bedside gaming, an indoor gymnasium, air hockey, arts and crafts and other activities as well as a secure outdoor area/fresh air space. The unit’s retention program includes education and tutoring. This unit was designed for the comfort of patients and family with two beds per room, which allows caregivers to stay overnight. It also allows separation from the adult populations on the larger 40-bed CRU. This unit is also being utilized for adult and elderly Phase I-Iia inpatient trials. It is equipped with PSG for sleep disorder trials, can conduct complex studies with serial PK draws and other special procedures.

Woodland Research Northwest, Rogers, AR – 24-Bed Clinical Research Unit/Outpatient Facility

In July 2016, WRN re-located to a new clinical research unit. This 12,000-square-foot site with 24 beds was purpose-built for subjects participating in clinical trials. The site is equipped with PSG for sleep disorders, can conduct complex studies with serial PK draws and other special procedures. Under the direction of Dr. Fayz Hudefi, the site continues to build on its experience in psychiatry and neurology while expanding into new therapeutic areas. Over the past year, WRN has been awarded/conducted studies in opioid withdrawal, Alzheimer’s disease, essential tremors, Post-Traumatic Stress Disorder, pediatric/adolescent Tourette’s Syndrome, migraine and Complex Regional Pain Syndrome. Dr. Robert Billingsley has joined WRN with extensive experience in psychiatric indications, specifically Schizophrenia and PTSD. He will serve as a Principal Investigator and rater.

WRN is planning for further expansion which will include a dedicated indoor smoking room and a 12-bed CPU designed for special populations.
Evolution Research Group has recently chosen StudyKIK, a clinical trial patient recruitment company that specializes in connecting quality patient groups through social media communities to clinical research sites, as its preferred recruitment provider for 2017. As preferred recruitment provider, StudyKIK will aid ERG and its wholly owned sites in identifying and enrolling subjects in difficult populations. “With protocols getting more complex and entry criteria becoming more challenging, sites have to adapt, be creative, and consistently look at new ways to identify quality subjects. That being said, the StudyKIK Platform, with its additional and upgraded offerings, has been a great tool for our sites. In addition, the StudyKIK team of knowledgeable and dedicated professionals is always responsive and able to meet our timelines and on certain studies, have been invaluable with helping us meet our enrollment goals,” stated Lori Wright, CEO of Evolution Research Group, and its wholly owned sites; Clinical Pharmacology of Miami, Midwest Clinical Research Center, Woodland International Research Group, St. Louis Clinical Trials, Woodland Research Northwest, and Pacific Research Network.

Evolution Research Group is a clinical research site organization comprised of seven fully owned and operated clinical research units, an affiliate network of 11 clinical sites and its consulting arm, Thievon-Wright Consulting Group. ERG as an organization, is focused on conducting simple and highly complex trials in psychiatric and neurologic disorders, non-CNS indications and early phase drug development. Under this new partnership, StudyKIK will strive to bring new patients to ERG’s research sites. “We are honored to represent Evolution Research Group and all its affiliate clinical research sites as preferred recruitment provider for 2017. I am certain that our advanced recruitment technology will bring an array of new patients to its network of sites,” said Jerome Chiaro, Vice President of Clinical Site Operations at StudyKIK.

To learn more about Evolution Research Group, visit www.joinaresearchstudy.com.